Neumora Therapeutics, Inc. (NMRA) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neumora Therapeutics, Inc. faces a material risk that failure to maintain its Nasdaq Global Select Market listing, including the $1.00 minimum bid price, could lead to delisting and significantly reduced liquidity. Such an outcome would likely depress trading price and volume, narrow the investor base, constrain financing options, and make it harder for stockholders to sell their shares.
Although the company recently regained compliance with Nasdaq’s bid price requirement after a prior deficiency notice, there is no assurance it will sustain compliance with this or other continued listing standards. Persistent or future listing challenges could weaken market visibility, reduce broker-dealer and market maker participation, and impair overall capital markets access for the company.
The average NMRA stock price target is $10.80, implying 459.59% upside potential.
To learn more about Neumora Therapeutics, Inc.’s risk factors, click here.